Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is expected to continue seeing strong growth and profitability due to its diverse portfolio of products targeting a broad range of therapeutic areas. The company's strong financials, including a revenue CAGR of 14% and a projected $130 billion in revenue by 2033E, support a positive outlook for its stock. Additionally, Eli Lilly's strategic focus on expanding its global manufacturing and its ability to develop and produce transformative medicines, such as Foundayo, make it well-positioned for future success and multiple expansion.

Bears say

Eli Lilly is facing challenges in its pricing strategies for its key products, with potential pressure from rebates and declining ASPs for Zepbound and Trulicity. There is also uncertainty around the success of tirzepatide and forglipron launch, as well as potential underperformance of pipeline products. While the company may see modest beats in TRx and projected revenue for Q2, there are downside risks and headwinds that could affect the company's financials and stock performance.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,302.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,302.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.